Celsion makes 33% jobs cut to salvage ThermoDox
This article was originally published in Scrip
Executive Summary
Buried near the bottom of a business update from Celsion to highlight a glimmer of efficacy for ThermoDox, which previously missed the primary endpoint in a Phase III liver cancer study, the company announced a "restructuring program" that will cut one-third of its work force.